US Biopharmaceuticals: Pipelines Unplugged call: BMY’s head of R&D (May 19th, 1pm ET)

Research evidence excerpt

US Biopharmaceuticals: Pipelines Unplugged call: BMY’s head of R&D (May 19th, 1pm ET)

Accessible version

US Biopharmaceuticals

Pipelines Unplugged call: BMY’s head of

R&D (May 19th, 1pm ET)

Invitation

Topic 15 May 2026

We are hosting Bristol Myers Squibb’s EVP, Chief Medical Office & Head of Equity

Development, Christian Massacesi, MD as part of our Pipelines Unplugged series. United States

Biopharmaceuticals

Why this call matters:

BMY is a catalyst-rich large cap biopharma with an extensive amount of pipeline data Related Research

flow in 2026-27. Among the topics we will discuss are: 1) cardiology: milvexian and

Camzyos programs; 2) hem-oncology: CELMoDs and cell therapy; 3) solid tumor Bristol-Myers Squibb: Fireside with BMY at BofA

oncology: PD-1/VEGF bispecific, ADC’s and targeted oncology; 4) neuroscience: Cobenfy Healthcare Conference in Las Vegas

life cycle programs; & 5) other: pivotal pulmonary (IPF/PPF). Bristol-Myers Squibb: 1Q26 wrap: mixed

quality beat; Buy on pipeline risk-reward

Beyond specific programs, the discussion will include broader R&D themes and

development considerations across therapeutic areas. US Biopharmaceuticals: Key ASCO 2026

presentations for our coverage

For more information on BMY, see these reports:

US Biopharmaceuticals: 2026 Catalyst

• May 15th: Bristol-Myers Squibb: Fireside with BMY at BofA Healthcare Preview: MRK, BMY, PFE, JNJ, LLY & 7 SMID-

Conference in Las Vegas Cap Biopharma Names

• Apr 20th: US Biopharmaceuticals: 2026 Catalyst Preview: MRK, BMY, PFE, JNJ, Bristol-Myers Squibb: YA26: Buy BMY given

LLY & 7 SMID-Cap Biopharma Names sector-low multiple & 4-6 catalysts that will

spark growth

• Jan 5th: US Biopharmaceuticals: Year Ahead 2026: Consolidation trend beneficial

across biopharma ecosystem

Abbreviations